July 13. 10:00 a.m. Mountain Time
Zoom link:
https://us06web.zoom.us/j/88163214349?pwd=FAAi5ykWJsIVZgOr8YJ6VO8cG7n8gA.1
To access the meeting, click on the link above, or copy and paste it into your web browser.
Signpath has developed a platform technology (the CorreQT platform) which mitigates the cardiac side effects of other drugs, including cardiac arrhythmia and cardiac damage associated with chemotherapy.
The first clinical application of Signpath’s CorreQT platform technology is LipoCurc™, a proprietary liposomal formulation of curcumin which is administered intravenously. LipoCurc’s proprietary technology provides for active and sustained levels of curcumin that are over 1000 times greater than traditional oral curcumin dosing, without the cardiotoxicity normally associated with intravenous curcumin administration.
LipoCurc™ has successfully completed Phase 1a and 1b clinical trials in 70 human subjects. Results of these trials showed no cardiac toxicity, and signs of efficacy in end-stage cancer patients who had failed 6-7 prior chemotherapy regimens. A Phase 2 trial in first line treatment of glioblastoma is underway. We are currently enrolling patients for this trial at Johns Hopkins University Hospital and are working to expand the number of clinical sites to add additional locations.
Additional information regarding this Phase 2 clinical trial can be found here: https://clinicaltrials.gov/study/NCT05768919?term=signpath&rank=1
Signpath’s patented CorreQT technology allows us to create new, cardiac safe versions of existing drugs. The lead CorreQT compound in development is SPP4040, a lipid-based drug which is administered orally. SPP4040 eliminates the dangerous cardiac arrhythmia and cardiac muscle damage which are common side effect of many other drugs. The CorreQT platform allows Signpath to create patented, next generation drugs with improved cardiac safety across multiple classes, including anti-cancer agents, antibiotics, antipsychotics, antihistamines and others.
LipoCurc™, Signpath’s patented Liposomal Curcumin product, was developed by researchers at the M.D. Anderson Cancer center, and exclusively licensed to Signpath. LipoCurc™ has completed Phase I human trials, exhibiting both efficacy and minimal toxicity at clinical doses. LipoCurc’s unique combination of mechanism pathways action includes inhibiting cancer checkpoint molecules that suppress the body’s immune response, as well as suppression of TNF alpha, IL-1 beta, IL-6, and Interferon gamma.
Signpath Pharma is headquartered in Sandy, Utah (a suburb of Salt Lake City.) We have partnerships and working relationships with labs, hospitals, and other companies in Canada, Europe, the U.S., and Asia.
Established in 2007 with the goal of developing Curcumin for cancer treatment, Signpath has since expanded into the area of cardiology, specifically the mitigation of pharmaceutical cardiac side effects.
We are committed to bringing innovative new treatments through the clinic and into the marketplace, addressing significant unmet medical needs.